Vitreous Humor Proteome: Targeting Oxidative Stress, Inflammation, and Neurodegeneration in Vitreoretinal Diseases
- PMID: 35326156
- PMCID: PMC8944522
- DOI: 10.3390/antiox11030505
Vitreous Humor Proteome: Targeting Oxidative Stress, Inflammation, and Neurodegeneration in Vitreoretinal Diseases
Abstract
Oxidative stress is defined as an unbalance between pro-oxidants and antioxidants, as evidenced by an increase in reactive oxygen and reactive nitrogen species production over time. It is important in the pathophysiology of retinal disorders such as diabetic retinopathy, age-related macular degeneration, retinal detachment, and proliferative vitreoretinopathy, which are the focus of this article. Although the human organism's defense mechanisms correct autoxidation caused by endogenous or exogenous factors, this may be insufficient, causing an imbalance in favor of excessive ROS production or a weakening of the endogenous antioxidant system, resulting in molecular and cellular damage. Furthermore, modern lifestyles and environmental factors contribute to increased chemical exposure and stress induction, resulting in oxidative stress. In this review, we discuss the current information about oxidative stress and the vitreous proteome with a special focus on vitreoretinal diseases. Additionally, we explore therapies using antioxidants in an attempt to rescue the body from oxidation, restore balance, and maximize healthy body function, as well as new investigational therapies that have shown significant therapeutic potential in preclinical studies and clinical trial outcomes, along with their goals and strategic approaches to combat oxidative stress.
Keywords: age-related macular degeneration; inflammation; neurodegeneration; oxidative stress; proliferative diabetic retinopathy; proliferative vitreoretinopathy; vitreous proteomics.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Vitreous humor proteome: unraveling the molecular mechanisms underlying proliferative and neovascular vitreoretinal diseases.Cell Mol Life Sci. 2022 Dec 31;80(1):22. doi: 10.1007/s00018-022-04670-y. Cell Mol Life Sci. 2022. PMID: 36585968 Free PMC article. Review.
-
Oxidative Stress, Inflammatory, Angiogenic, and Apoptotic molecules in Proliferative Diabetic Retinopathy and Diabetic Macular Edema Patients.Int J Mol Sci. 2023 May 4;24(9):8227. doi: 10.3390/ijms24098227. Int J Mol Sci. 2023. PMID: 37175931 Free PMC article.
-
Gelatinase B in proliferative vitreoretinal disorders.Am J Ophthalmol. 1998 Jun;125(6):844-51. doi: 10.1016/s0002-9394(98)00041-5. Am J Ophthalmol. 1998. PMID: 9645722
-
[The pathogenesis of vitreoretinal diseases from the standpoint of molecular biology].Nippon Ganka Gakkai Zasshi. 2003 Dec;107(12):785-812. Nippon Ganka Gakkai Zasshi. 2003. PMID: 14733131 Review. Japanese.
-
Systems pathology analysis identifies neurodegenerative nature of age-related vitreoretinal interface diseases.Aging Cell. 2018 Oct;17(5):e12809. doi: 10.1111/acel.12809. Epub 2018 Jul 2. Aging Cell. 2018. PMID: 29963742 Free PMC article.
Cited by
-
Vitreous humor proteome: unraveling the molecular mechanisms underlying proliferative and neovascular vitreoretinal diseases.Cell Mol Life Sci. 2022 Dec 31;80(1):22. doi: 10.1007/s00018-022-04670-y. Cell Mol Life Sci. 2022. PMID: 36585968 Free PMC article. Review.
-
Ferroptosis in ocular diseases: mechanisms, crosstalk with other cell death pathways, and therapeutic prospects.Front Med (Lausanne). 2025 Jul 8;12:1608975. doi: 10.3389/fmed.2025.1608975. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40697914 Free PMC article. Review.
-
Serum and Vitreous Levels of Placenta Growth Factor in Diabetic Retinopathy Patients: Correlation With Disease Severity and Optical Coherence Tomographic Parameters.Cureus. 2024 Feb 25;16(2):e54862. doi: 10.7759/cureus.54862. eCollection 2024 Feb. Cureus. 2024. PMID: 38533176 Free PMC article.
-
Inflammation and Oxidative Stress Gene Variability in Retinal Detachment Patients with and without Proliferative Vitreoretinopathy.Genes (Basel). 2023 Mar 27;14(4):804. doi: 10.3390/genes14040804. Genes (Basel). 2023. PMID: 37107562 Free PMC article.
-
Plasmid Gene Therapy for Monogenic Disorders: Challenges and Perspectives.Pharmaceutics. 2025 Jan 14;17(1):104. doi: 10.3390/pharmaceutics17010104. Pharmaceutics. 2025. PMID: 39861752 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources